A study was recently completed in Australia to assess the effectiveness of Libifem on normal symptoms of menopause in otherwise healthy women.  This 12-week, double-blind, randomized, placebo-controlled clinical trial was conducted on women who were experiencing symptoms of menopause and were aged between 40 to 65 years.

The primary outcome measure was a reduction in menopausal symptoms, assessed by the validated Menopause-Specific Quality of Life Questionnaire (MENQOL). Secondary outcome measures were an increase of serum sex hormone levels and improvement of quality of life.

​

In another 8 weeks placebo-controlled study, it shows Libifem has the ability in supporting female sexual desire, libido, hormone levels and the metabolism on 80 healthy females in stable relationships.